Abstract
Proton magnetic resonance spectroscopy (1H MRS) enables the observation of brain function in vivo. Several brain metabolites can be measured by the means of 1H MRS: N-acetylaspartate (NAA), choline containing compounds (Cho), myo-inositol (mI) and glutamate (Glu), glutamine (Gln) and GABA (together as Glx complex or separately). 1H MRS measures have been found to be abnormal in psychotic disorders such as schizophrenia. Here we specifically review the influence exerted by antipsychotic drugs on brain metabolism, as detected by1H MRS. We systematically reviewed the available literature and uncovered 27 studies, 16 before-after treatment and 11 cross-sectional. Most of them addressed the effects of antipsychotics in schizophrenia and mainly focusing on NAA alterations. Follow up studies indicated antipsychotic drugs may act by increasing NAA levels in selected brain areas (the frontal lobe and thalamus), especially during the short-time observation. This phenomenon seems to vanish after longer observation. Other studies indicated that glutamate measures are decreasing along with the duration of the disease, suggesting both a neurodegenerative process present in schizophrenic brain as well as an influence of antipsychotics.
The above results were reviewed according to the most recent theories in the field accounting for the impact of antipsychotics 1HMRS measures.Keywords: Antipsychotics, proton magnetic resonance spectroscopy, schizophrenia, bipolar disorder, N-acetylaspartate, glutamate, psychosis
Current Medicinal Chemistry
Title:Proton Magnetic Resonance Spectroscopy Changes After Antipsychotic Treatment
Volume: 20 Issue: 3
Author(s): Agata Szulc, Beata Galinska-Skok, Napoleon Waszkiewicz, Daniel Bibulowicz, Beata Konarzewska and Eugeniusz Tarasow
Affiliation:
Keywords: Antipsychotics, proton magnetic resonance spectroscopy, schizophrenia, bipolar disorder, N-acetylaspartate, glutamate, psychosis
Abstract: Proton magnetic resonance spectroscopy (1H MRS) enables the observation of brain function in vivo. Several brain metabolites can be measured by the means of 1H MRS: N-acetylaspartate (NAA), choline containing compounds (Cho), myo-inositol (mI) and glutamate (Glu), glutamine (Gln) and GABA (together as Glx complex or separately). 1H MRS measures have been found to be abnormal in psychotic disorders such as schizophrenia. Here we specifically review the influence exerted by antipsychotic drugs on brain metabolism, as detected by1H MRS. We systematically reviewed the available literature and uncovered 27 studies, 16 before-after treatment and 11 cross-sectional. Most of them addressed the effects of antipsychotics in schizophrenia and mainly focusing on NAA alterations. Follow up studies indicated antipsychotic drugs may act by increasing NAA levels in selected brain areas (the frontal lobe and thalamus), especially during the short-time observation. This phenomenon seems to vanish after longer observation. Other studies indicated that glutamate measures are decreasing along with the duration of the disease, suggesting both a neurodegenerative process present in schizophrenic brain as well as an influence of antipsychotics.
The above results were reviewed according to the most recent theories in the field accounting for the impact of antipsychotics 1HMRS measures.Export Options
About this article
Cite this article as:
Szulc Agata, Galinska-Skok Beata, Waszkiewicz Napoleon, Bibulowicz Daniel, Konarzewska Beata and Tarasow Eugeniusz, Proton Magnetic Resonance Spectroscopy Changes After Antipsychotic Treatment, Current Medicinal Chemistry 2013; 20 (3) . https://dx.doi.org/10.2174/0929867311320030013
DOI https://dx.doi.org/10.2174/0929867311320030013 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
PAX6 expression may be protective against dopaminergic cell loss in Parkinson’s disease
CNS & Neurological Disorders - Drug Targets Variability in the Effects of Nicotine on Different Regions of the Brain: Changes in the Concentration of Superoxide Dismutase Isoforms
Central Nervous System Agents in Medicinal Chemistry The Sam Domain of EphA2 Receptor and its Relevance to Cancer: A Novel Challenge for Drug Discovery?
Current Medicinal Chemistry Novel Approaches for Modulating dUTPase and Uracil-DNA Glycosylase: Potential Uses for Cancer and Viral Chemotherapy
Drug Design Reviews - Online (Discontinued) CAR T-cell Therapy: A New Era in Cancer Immunotherapy
Current Pharmaceutical Biotechnology Toll-Like Receptors: Cost or Benefit for Cancer?
Current Pharmaceutical Design Impact of Diabetes in Blood-Testis and Blood-Brain Barriers: Resemblances and Differences
Current Diabetes Reviews Multifunctional Role of Pacap-Like Peptides in Molluscs
Protein & Peptide Letters Telomerase Modulation in Therapeutic Approach
Current Pharmaceutical Design Modulation of GSTP1-1 Oligomerization by Electrophilic Inflammatory Mediators and Reactive Drugs
Inflammation & Allergy - Drug Targets (Discontinued) Involvement of Uridine-Nucleotide-Stimulated P2Y Receptors in Neuronal Growth and Function
Central Nervous System Agents in Medicinal Chemistry Carbon Nanotubes in the Diagnosis and Treatment of Malignant Melanoma
Anti-Cancer Agents in Medicinal Chemistry Chemotherapy In Japanese Encephalitis: Are We There Yet?
Infectious Disorders - Drug Targets The Clinical Prognostic Value of LRG1 in Esophageal Squamous Cell Carcinoma
Current Cancer Drug Targets Flavonoids Protect Cerebrovascular Endothelial Cells through Nrf2 and PI3K from β-Amyloid Peptide-Induced Oxidative Damage
Current Neurovascular Research HSV Amplicons: Neuro Applications
Current Gene Therapy Protein Kinases as Tumor Biomarkers and Therapeutic Targets
Current Pharmaceutical Design Editorial [Hot Topic:Treatment of Neuroblastoma: From Cellular to Molecular Therapy (Executive Editor: Gian Paolo Tonini)]
Current Pharmaceutical Design Protein Modification by β-N-Acetyl Glucosamine (O-GlcNAc) in Insulin Signaling and Insulin Resistance
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Gene Therapy for Parkinsons Disease: Progress and Challenges
Current Gene Therapy